Scrip
>>Business

Myovant's Next Act: Commercial Execution And Business Development

08 Mar 2022

The company is ramping up the launches of Orgovyx for prostate cancer and Myfembree for uterine fibroids, including indication and geographic expansions, and evaluating business development opportunities.

flower blossom — Myovant hopes its budding commercial brands will blossom • Source: Alamy

Having launched the gonadotropin-releasing hormone (GnRH) antagonist relugolix as Orgovyx for prostate cancer and Myfembree for the treatment of bleeding associated with uterine fibroids in the US in 2021, Myovant Sciences Ltd. is now focused on building commercially successful brands and establishing the next pillars for growth.

"These launches are off to a good start in 2021, and now we are looking for real growth as we enter 2022," CEO David Marek said on 8 March at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

02 Jun 2025

• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.